Supernus Pharmaceuticals SUPN Business Segments — Selling expenses
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:SellingExpense.
The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Supernus Pharmaceuticals's business segments — selling expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Supernus Pharmaceuticals's business segments — selling expenses?
- Supernus Pharmaceuticals (SUPN) reported business segments — selling expenses of $66.28M in Q1 2026.
- How has Supernus Pharmaceuticals's business segments — selling expenses changed year-over-year?
- Supernus Pharmaceuticals's business segments — selling expenses increased by 55.5% year-over-year, from $42.61M to $66.28M.
- What is the long-term trend for Supernus Pharmaceuticals's business segments — selling expenses?
- Over 3 years (2022 to 2025), Supernus Pharmaceuticals's business segments — selling expenses has grown at a 12.5% compound annual growth rate (CAGR), from $147.29M to $209.7M.
- What does business segments — selling expenses mean?
- Captures the costs incurred by the sales force to promote and distribute pharmaceutical products to healthcare providers. These expenditures are critical for driving market penetration and maintaining physician awareness of the company's therapeutic offerings.